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2Joint WHO/UNODC/UNAIDS statement 
on substitution maintenance therapy1
 Opioid dependence, a complex health condition that often requi-
res long-term treatment and care, is associated with a high risk 
of HIV infection when opioids are injected using contaminated 
injection equipment. Drug dependence treatment is an important 
strategy to improve well-being and social functioning of people 
with opioid dependence and to reduce its health and social con-
sequences, including HIV infection. As no single treatment is effec-
tive for all individuals with opioid dependence, sufficiently diverse 
treatment options should be available. Substitution maintenance 
therapy is one of the most effective treatment options for opioid 
dependence. It can decrease the high cost of opioid dependence 
to individuals, their families and society at large by reducing 
heroin use, associated deaths, HIV risk behaviours and criminal 
activity. Substitution maintenance therapy is a critical component 
of community-based approaches in the management of opioid 
dependence and the prevention of HIV infection among injecting 
drug users (IDUs). Provision of substitution maintenance therapy 
– guided by research evidence and supported by adequate eva-
luation, training and accreditation – should be considered as an 
important treatment option in communities with a high preva-
lence of opioid dependence, particularly those in which opioid 
injection places IDUs at risk of transmission of HIV and other 
bloodborne viruses. 
1 In this document the term “substitution maintenance therapy” refers to treatment 
fulfilling the following criteria: agents used for substitution therapy have been 
thoroughly evaluated; treatment is administered by accredited professionals in 
the framework of recognized medical practice; and there is appropriate clinical 
monitoring. 
Introduction
4Epidemiology and burden of opioid use2 
and dependence
1 Opiates are a group of psychoactive substances derived from 
the poppy plant, that includes opium, morphine, codeine and 
some others. The term “opiate” is also used for the semisynthetic 
drug heroin that is produced from poppy compounds. The term 
“opioids” refers to opiates and other semisynthetic and synthetic 
compounds with similar properties. Opioids are dependence pro-
ducing substances, which elicit their effects by activating opioid 
receptors in the brain. Opioids are generally consumed by injec-
tion, oral ingestion or inhalation of the fumes produced by hea-
ting. Regular use of opioids can lead to opioid dependence.
2 Opioid users constitute only a very small proportion of the world 
population (less than 1% of those aged 15 years and above). Parts 
of the world where opioid use and related problems are predo-
minant include North America, Western, South and South-East 
Asia, Europe, and the Middle East. Injection opioid use has rapidly 
increased in Central Asia and in Central and Eastern Europe. Recent 
information also indicates that pockets of opioid injection have 
emerged in some urban centres in Africa, and the levels of opioid 
use are higher than was previously thought in Africa.
3 The cost of opioid use to individual users and to society as a 
whole, is high. Studies indicate that opioid dependence results in 
significant costs to society through unemployment, homelessness, 
family disruption, loss of economic productivity, social instability 
and criminal activities. Major health consequences of opioid use 
include higher risk of premature death and, when opioids are 
injected, increased risk of bloodborne infections such as HIV and 
hepatitis B and C.
 2 In this document the term “opioid use/user” is utilized to refer to any form, level 
and pattern of non-medical use of opioids, including occasional and prolonged 
consumption.
54 Individuals with opioid dependence – who often inject drugs 
of unknown potency and quality and in conjunction with other 
substances – frequently experience overdose, with a high risk of 
death. Longitudinal studies suggest that approximately 2–3% of 
them die each year. The mortality rate for dependent heroin users 
is between 6 and 20 times that expected for those in the general 
population of the same age and gender. 
5 Globally, between 5 and 10% of HIV infections result from injection 
drug use; however, in some countries in Asia and Europe, over 70% 
of HIV infections are attributed to injection drug use, with opioids 
being the most commonly injected drugs in these regions. 
6 Injecting drug users (IDUs) are vulnerable to infection with HIV 
and other bloodborne viruses as a result of sharing/reusing injec-
ting equipment and drug solution, sexual contact with other IDUs, 
and high-risk sexual activity. Although most IDUs are males, female 
drug users may be more vulnerable to HIV than their male coun-
terparts, as they are more likely to use their partner’s injecting 
equipment and it is often difficult for them to negotiate low-risk 
sexual practices and condom use. IDUs are relatively more likely to 
be involved in the sex industry. 
7 Injection drug use is now the dominant mode of transmission of 
hepatitis C virus. Infection with hepatitis C virus results in chronic 
infection in at least 50–85% of cases. Approximately 7–15% of 
chronically infected persons progress to liver cirrhosis within 20 
years and of these, a proportion will subsequently develop liver 
cancer. 
68 There are strong links between opioid use and dependence, and 
criminal behaviour: people with opioid dependence often commit 
crimes to obtain money to purchase drugs; crimes are committed 
under the influence of drugs; and there is an overlap between the 
factors associated with the development of criminal behaviour 
and those associated with the initiation of illicit drug use. The cri-
minal offences involved are generally acquisitive crime, drug traf-
ficking or sex trade.
9 It has been estimated that in some countries around three-
quarters of people in prison have alcohol or other drug-related 
problems, and more than one-third may be opioid dependent. 
Around one-third will have been imprisoned for drug-related 
offences. Some level of continued drug use often occurs in pri-
son and is usually associated with high risk of HIV transmission 
due to sharing/reusing injecting equipment and drug solution. 
On release, prisoners with opioid dependence are at high risk of 
relapse and overdose. Consequently, substitution therapy is pro-
vided to inmates of correctional facilities in some countries. The 
costs of law enforcement, court time and imprisonment together 
contribute substantially to the social costs associated with opioid 
dependence. In general, studies indicate that pure criminal justice 
interventions, without associated opioid dependence treatment, 
have very limited impact on drug-using behaviour and re-offen-
ding among individuals with drug dependence. 
710 Opioid dependence develops after a period of regular use of 
opioids, with the time required varying according to the quan-
tity, frequency and route of administration, as well as factors of 
individual vulnerability and the context in which drug use occurs. 
Opioid dependence is not just a heavy use of opioids, but a com-
plex health condition that has social, psychological and biological 
determinants and consequences, including changes in the brain. It 
is not a weakness of character or will. 
11 The key elements of opioid dependence are: a strong desire or 
sense of compulsion to take opioids; difficulties in controlling 
opioid-taking behaviour; a withdrawal state when opioid use 
has ceased or been reduced; evidence of tolerance, such that 
increased doses are required to achieve effects originally produ-
ced by lower doses; progressive neglect of alternative pleasures or 
interests; and persistence with opioid use despite clear evidence 
of overtly harmful consequences. It is these aspects that make 
opioid dependence particularly damaging to the individual, family 
and community. 
Nature of opioid dependence
812 Treatment of opioid dependence is an important strategy to 
address the health and social consequences associated with drug 
dependence at individual and societal levels. Failure to provide 
adequate treatment for opioid dependence is generally costly to 
health services and to the community. 
13 As with other health conditions such as hypertension, diabetes 
and heart disease, people with opioid dependence can stabilize 
their condition by developing and incorporating behavioural 
changes and by appropriate use of medications. 
14 Relapse following detoxification alone is extremely common, and 
therefore detoxification rarely constitutes an adequate treatment 
of substance dependence on its own. Simple detoxification or 
stopping opioid use is often insufficient: a therapeutic process 
is required. Detoxification, however, is a first step for many forms 
of longer-term abstinence-based treatment. Both detoxification 
with subsequent abstinence-oriented treatment and substitution 
maintenance treatment are essential components of an effective 
treatment system for people with opioid dependence.
15 The main objectives of treating and rehabilitating persons with 
opioid dependence are as follows: to reduce dependence on illicit 
drugs; to reduce the morbidity and mortality caused by the use 
of illicit opioids, or associated with their use, such as infectious 
diseases; to improve physical and psychological health; to reduce 
criminal behaviour; to facilitate reintegration into the workforce 
and education system and to improve social functioning. The ulti-
mate achievement of a drug free state is the ideal and long-term 
objective but this is unfortunately not feasible for all individuals 
with opioid dependence, especially in the short term. An exclu-
sive focus on achieving a drug free state as an immediate goal for 
all patients may jeopardize the achievement of other important 
objectives such as HIV prevention. 
Treatment of opioid dependence: 
objectives and principle
916 No single treatment is effective for all individuals. Individuals see-
king treatment for opioid dependence will have different patterns 
of risk and protective factors, and different psychological and 
social problems. Therefore services should be sufficiently varied 
and flexible to respond to the needs of clients, their severity of 
dependence, personal circumstances, motivation and response to 
interventions. The rational management of opioid dependence 
calls for the balanced combination of pharmacotherapy, psycho-
therapy, psychosocial rehabilitation and risk reduction interven-
tions.
17 Treatment should be readily available. Most people with opioid 
dependence express a strong desire to be abstinent but remain 
ambivalent about treatment. Frequently a crisis (financial, legal, 
physical health, partner or family) triggers a treatment episode. 
Consequently, it is important that treatment is readily available to 
take advantage of the motivation created by these crises.
18 Remaining in treatment for an adequate period of time is critical 
for treatment effectiveness. The appropriate duration of treat-
ment for an individual depends on their problems and needs, but 
research indicates that for most people with drug dependence, the 
threshold of significant improvement is reached after about three 
months in treatment, with further gains as treatment is continued. 
Because people often leave treatment prematurely, and premature 
departure is associated with high rates of relapse to drug use, pro-
grammes should include strategies to engage and keep patients 
in treatment. Many patients need several years in treatment. 
19 For those individuals who are currently unable or unwilling to stop 
using drugs, treatment interventions should be directed at reduc-
tion of morbidity, disability and death caused by, or associated 
with, substance use. Reduction in risk behaviours associated with 
drug dependence is an achievable goal. 

Substitution 
therapy of opioid 
dependence
12
Definition of substitution therapy and the 
rationale for substitution maintenance therapy 
in the management of opioid dependence
20 Substitution therapy (“agonist pharmacotherapy”,  “agonist repla-
cement therapy”,  “agonist-assisted therapy”) is defined as the 
administration under medical supervision of a prescribed psy-
choactive substance, pharmacologically related to the one pro-
ducing dependence, to people with substance dependence, for 
achieving defined treatment aims. Substitution therapy is widely 
used in the management of nicotine (“nicotine replacement the-
rapy”) and opioid dependence.
21 Agents suitable for substitution therapy of opioid dependence are 
those with some opioid properties so that they have the capacity 
to prevent the emergence of withdrawal symptoms and reduce 
craving. At the same time, they diminish the effects of heroin or 
other opioid drugs because they bind to opioid receptors in the 
brain. In general, it is desirable for opioid substitution medicines 
to have a longer duration of action than the drug they are repla-
cing so as to delay the emergence of withdrawal and reduce the 
frequency of administration, thereby resulting in less disruption of 
normal life activities by the need to obtain and administer medi-
cines. Whereas illicitly used opioids are usually injected or inhaled 
by drug users, these prescribed medicines are usually administe-
red orally in the form of a tablet or a solution, thereby reducing 
the risk of infections associated with injections. 
22 Medicines used in substitution therapy can be prescribed either 
in decreasing doses over short periods of time (usually less than 
one month) for treatment of withdrawal or for detoxification, or 
in relatively stable doses over a long period of time (usually more 
than six months) for substitution maintenance therapy, which 
allows stabilization of brain functions and prevention of craving 
and withdrawal. The term “substitution therapy” is often utilized as 
an equivalent to “substitution maintenance therapy”.
13
23 Substitution maintenance therapy is one of the most effective 
types of pharmacological therapy of opioid dependence. There 
is consistent evidence from numerous controlled trials, large lon-
gitudinal studies and programme evaluations, that substitution 
maintenance treatment for opioid dependence is associated with 
generally substantial reductions in illicit opioid use, criminal acti-
vity, deaths due to overdose, and behaviours with a high risk of 
HIV transmission.
24 Substitution maintenance therapy of opioid dependence is an 
important component of community-based approaches in that 
the treatment can be provided on an out-patient basis, achieving 
high rates of retention in treatment and increasing the time and 
opportunity for individuals to tackle major health, psychological, 
family, housing, employment, financial and legal issues while in 
contact with treatment services.
25 The prescription for substitution therapy and administration of 
opioid agonists to persons with opioid dependence – in the fra-
mework of recognized medical practice approved by competent 
authorities – is in line with the 1961 and 1971 Conventions on nar-
cotic drugs and psychotropic substances. 
14
Methadone
26 Methadone is a synthetic opioid that is typically administered oral-
ly as a liquid. Methadone is the medication that is most commonly 
used for substitution therapy of opioid dependence. Methadone 
maintenance treatment is also an extensively researched treat-
ment modality. There is strong evidence, from research and moni-
toring of service delivery, that substitution maintenance therapy 
with methadone (methadone maintenance treatment) is effective 
in reducing illicit drug use, reducing mortality, reducing the risk 
of spread of HIV, improving physical and mental health, impro-
ving social functioning and reducing criminality. Higher doses of 
methadone are generally associated with greater reductions in 
heroin use than either moderate or low doses.
27 Methadone maintenance treatment is associated with a low inci-
dence of side-effects and with substantial health improvements. 
Around three-quarters of people who commence substitution 
maintenance therapy with methadone respond well. However, for 
various reasons, methadone does not suit all people with opioid 
dependence. For this group it is important that alternative approa-
ches are available to encourage their retention in treatment. Some 
require several episodes of treatment before major progress is 
achieved. 
Pharmacological agents used for opioid 
substitution maintenance therapy
15
Buprenorphine
28 Buprenorphine is a prescribed medication with weaker opioid 
agonist activity than methadone. Buprenorphine is not well absor-
bed if taken orally, therefore the usual route of administration in 
treatment of opioid dependence is sublingual. With increasing 
doses of buprenorphine, effects reach a plateau. Consequently, 
buprenorphine is less likely than either methadone or heroin to 
cause an opioid overdose condition, even when taken with other 
opioids at the same time. The effectiveness of buprenorphine is 
similar to that of methadone at adequate doses, in terms of reduc-
tion of illicit opioid use and improvements in psychosocial func-
tioning, but buprenorphine may be associated with lower rates of 
retention in treatment. Buprenorphine is currently more expensive 
than methadone.
29 Buprenorphine is acceptable to heroin users, has few side-effects, 
and is associated with a relatively mild withdrawal syndrome. 
When used in opioid substitution therapy for pregnant women 
with opioid dependence, it appears to be associated with a lower 
incidence of neonatal withdrawal syndrome. 
16
Other pharmacological agents
30 Levo alpha acetyl methadol (LAAM), like methadone, is a synthetic 
opioid which is effective when ingested orally. LAAM and metha-
done are of approximately equivalent effectiveness in terms of 
capacity to reduce illicit drug use, but LAAM has a slower onset of 
action and a longer duration of action compared to methadone, 
and can be administered every three days, providing greater flexi-
bility for clients, with less need for unsupervised doses and thus 
less opportunity for dose diversion. LAAM is used in the United 
States of America, but in the European Union it has been removed 
from the therapeutic arena because of concerns about a possible 
effect on cardiac function.
31 Dihydrocodeine is used in some countries for detoxification and 
substitution maintenance therapy. Tincture of opium (laudanum) 
is used in some countries in Asia for the management of opioid 
withdrawal and, less commonly, for substitution maintenance the-
rapy. The various oral preparations of morphine formulated to pro-
vide slow release (also called sustained release, controlled release 
and timed release preparations) are also of potential value in the 
treatment of opioid dependence. However, controlled studies of 
the effectiveness of these preparations for substitution treatment 
are yet to be undertaken.
17
32 The approach of providing medically prescribed diacetylmorphine 
(heroin) as an opioid substitution maintenance treatment has 
been the subject of extensive public debate, but has received rela-
tively little research. National projects in the Netherlands and in 
Switzerland have assessed the feasibility of using medically pres-
cribed diacetylmorphine as a treatment for severely dependent 
individuals. In both countries patients who had previously failed 
in methadone treatment were successfully engaged in treatment 
with diacetylmorphine. The relative contribution of the provision 
of psychosocial support concomitant to diacetylmorphine pres-
cription on treatment outcomes is a subject for further research. 
The approach of prescribing diacetylmorphine is complex and 
costly and has been evaluated only in countries with well-develo-
ped treatment systems. Results from such evaluations indicate that 
in comprehensive treatment systems it might be an alternative for 
a small proportion of severely dependent long-term patients for 
whom other treatment options have been ineffective. 
18
Benefits
33 Several longitudinal studies examining changes in HIV risk beha-
viours for patients currently in treatment have found that longer 
retention in treatment, as well as completion of treatment, are 
correlated with reduction in HIV risk behaviours related to drug-
taking or an increase in protective behaviours. IDUs who do not 
enter treatment are up to six times more likely to become infected 
with HIV than injectors who enter and remain in treatment. 
34 Substitution maintenance therapy of opioid dependence has been 
found to be more effective than placebo and detoxification alone 
in retaining opioid-dependent people in treatment and reducing 
heroin use. 
35 The death rate for people with opioid dependence in methadone 
maintenance treatment is one-third to one-quarter the rate for 
those not in treatment. 
36 There are fewer complications for pregnant women and their 
unborn children who are in substitution maintenance treatment in 
comparison with those who are not in treatment.
Impact of opioid substitution 
maintenance therapy 
19
37 Substitution maintenance therapy has also been associated with 
higher legitimate annual earnings. Some studies have indicated 
improved levels of employment and other indicators of social 
functioning associated with methadone maintenance treatment, 
but data on these aspects are limited. Assessment of the impact of 
substitution maintenance therapy on social dimensions is made 
difficult by the influence of other factors, including the social cli-
mate in which studies occur, and the circumstances of patients 
prior to treatment.
38 Several studies have recorded very high levels of criminal involve-
ment by drug users before entering treatment, with these levels 
reduced by around one-half after a year of methadone maintenan-
ce treatment. Benefits are greatest during and immediately after 
treatment, but nonetheless, significant improvements remain for 
several years after treatment. Reductions are most marked in drug-
related criminal behaviour.
Risks
39 The most significant risk of methadone and other opioid agonists 
is overdose, which can be fatal. Research evidence indicates that 
the highest risk of overdose is during commencement of metha-
done substitution treatment. Therefore, low doses are recommen-
ded at the beginning of treatment. However, once a stable dose 
is achieved (about two weeks) the risk of overdose death is then 
substantially reduced in comparison with the risk prior to treat-
ment. 
20
40 There is a risk of diversion into illicit channels of the medications 
used for substitution treatment, as with other narcotic and psycho-
tropic substances under international control. Effective imple-
mentation of national and international drug control procedures, 
and other mechanisms such as supervised administration of medi-
cation, can work together to minimize such risks. 
Factors influencing treatment outcome
41 It is clear from research evidence that the effectiveness of opioid 
substitution maintenance therapy is dependent on timely entry 
into treatment, adequate medication dosage, duration and conti-
nuity of treatment, and accompanying medical and psychosocial 
services. In programmes that use higher doses of methadone, 
a majority of patients are retained in treatment for at least 12 
months. Research indicates that higher doses of buprenorphine 
and LAAM are also more effective than lower doses. In all cases it is 
important that the dose selected is based on an assessment of the 
individual patient. Constructive (non-punitive) clinic responses to 
client problems improve retention and treatment outcomes.
42 Substitution treatment for opioid dependence on its own is asso-
ciated with reductions in illicit opioid use. However, there is evi-
dence that the addition of psychosocial therapy adds to the ove-
rall effectiveness of substitution treatment programmes. Research 
evidence indicates that counselling is important for those who 
need it, but can be counter-productive if mandated.
21
Cost–effectiveness
43 Opioid dependence treatment is effective in reducing illicit opioid 
use and its associated health and social costs. Treatment is consi-
derably less expensive than alternatives, such as not treating peo-
ple with opioid dependence, or imprisonment.
44 According to several conservative estimates, every dollar invested 
in opioid dependence treatment programmes may yield a return 
of between $4 and $7 in reduced drug-related crime, criminal jus-
tice costs and theft alone. When savings related to health care are 
included, total savings can exceed costs by a ratio of 12:1. 
45 There is scientific evidence that substitution maintenance therapy is 
a cost-effective treatment modality with cost–effectiveness measu-
res comparing favourably with other health care interventions, such 
as medical therapy for severe hypertension or for HIV/AIDS. 
22
46 Drug demand reduction and HIV prevention programmes should 
be integrated into broader social welfare and health promotion 
policies and preventive education programmes. Specifi c 
interventions should be based on regular assessment of the 
nature and magnitude of drug dependence and related disorders, 
as well as trends and patterns of HIV infection. A structured natio-
nal HIV prevention programme should include comprehensive 
treatment of drug dependence, including substitution maintenan-
ce therapy for opioid dependence, where opioid injection places 
IDUs at risk of transmission of HIV and other bloodborne viruses. 
47 Given the scale of problems in most societies and the limited 
resources available, a clear and coherent approach to service plan-
ning is required. Overall, there is a need to develop services that 
can reach the maximum number of individuals and have the grea-
test impact at lowest cost. This is most likely to be achieved with 
broad community-based services that can work with individuals in 
their own communities over longer periods of time.
48 In countries with a significant prevalence of heroin or other opioid 
dependence, methadone and/or other substitution maintenance 
treatment programmes should be considered as one useful treat-
ment option in an overall national drug treatment policy. 
49 Such programmes and interventions should build on knowled-
ge and expertise acquired from research, including empirical 
knowledge about the social milieu around which drug taking 
revolves, as well as lessons learned from the implementation of 
previous projects and interventions. In countries with no expe-
rience of substitution maintenance therapy, pilot projects should 
be implemented for possible later application at national level. 
Opioid substitution maintenance therapy 
as part of a health care system
23
50 So far, with few exceptions, the provision of opioid substitution 
maintenance therapy around the world has largely been imple-
mented in specialized drug dependence treatment programmes, 
separated from general health services. Treatment of large num-
bers of individuals with opioid dependence, however, demands 
the development of community-based health and social services, 
and the development of substitution maintenance treatment pro-
grammes that are incorporated within general primary health care 
and welfare services.
51 Participation in substitution maintenance therapy provides oppor-
tunities for early diagnosis of other health problems, for counsel-
ling and testing, and referral for additional services. The best drug 
dependence treatment programmes provide counselling and tes-
ting for both HIV and viral hepatitis, as well as hepatitis immuniza-
tion, with due attention also given to counselling on the reduction 
of sexual risk behaviour. In addition, drug treatment programmes 
need to be involved in provision of HIV/AIDS treatment, care and 
support, as necessary, to their clients. 
24
52 Substitution maintenance therapy has proven effective in terms 
of retention in treatment, reduction of drug use, improvement of 
psychological and social functioning, and reduction of high risk 
injecting and sexual behaviours. As such, substitution mainte-
nance therapy should be given serious consideration not only as 
an HIV prevention measure, but also for individuals with opioid 
dependence who are already infected with HIV, so as to minimize 
the risk of further transmission of the virus and to stabilize their 
underlying condition. 
53 Treatment for people with HIV infection who are drug dependent 
must address clinical and psychosocial issues related to both con-
ditions. The combination of opioid dependence and HIV infection 
can result in specific clinical situations such as the occurrence of 
particular HIV-related opportunistic infections; the masking of 
HIV-AIDS related symptoms by substitution medication; and inte-
ractions between opioid substitute medications and medications 
used to manage HIV infection. Those treating opioid dependence 
in persons with HIV/AIDS need to be aware of these clinical situa-
tions. Conversely, those treating individuals with both HIV/AIDS 
and opioid dependence need to be familiar with common approa-
ches to the treatment of opioid dependence and related problems. 
54 Drug use in individuals with opioid dependence may interfere 
with adherence to treatment regimens for HIV/AIDS, and it is there-
fore imperative that treatment for opioid dependence is initiated 
to support adherence to antiretroviral treatment and medical 
follow-up. It has been demonstrated that stopping drug injecting 
slows the progression of HIV disease in infected subjects.
Provision of opioid substitution maintenance 
therapy to people with opioid dependence 
and HIV/AIDS 
25
55 People with both opioid dependence and HIV/AIDS are often 
doubly stigmatized. In many countries they are excluded from the 
provision of antiretroviral treatment in spite of the evidence that 
individuals with opioid dependence benefit from appropriately 
administered HIV/AIDS drug treatment, as do individuals without 
opioid dependence. Programmes that integrate substitution main-
tenance therapy of opioid dependence with HIV/AIDS treatment 
and care should therefore be encouraged. Directly observed the-
rapy for opioid dependence also provides an opportunity for the 
implementation of directly observed antiretroviral therapy as well 
as therapy for opportunistic infections such as tuberculosis.
26
Special considerations in provision of opioid 
substitution maintenance treatment 
56 While there is evidence of effectiveness of substitution maintenan-
ce therapy across a variety of cultural and ethnic groups and social 
contexts, a number of factors are recognized, which influence 
treatment outcomes in some communities, including socioecono-
mic status, poverty, differences in educational opportunities, and 
cultural responsiveness of treatment programmes. It will therefore 
be necessary to respond to the diverse needs and characteristics 
of different target groups when designing opioid dependence 
treatment programmes, in order to ensure equally good treatment 
outcomes. 
57 Women tend to have a different experience with both drug 
dependence and treatment, from that of men. There are major 
issues related to the high levels of both physical and psychological 
comorbidity of women with opioid dependence, which need to 
be taken into account in the provision of treatment. Females with 
opioid dependence often face a variety of barriers to treatment, 
including lack of financial resources, absence of services and refer-
ral networks oriented to women, and conflicting childcare res-
ponsibilities. In many countries increasing proportions of women 
prisoners have polysubstance dependence, including opioid 
dependence. Organizing appropriate treatment in this environ-
ment continues to be a major challenge.
58 Effective pharmacotherapy treatment of opioid dependence can 
substantially improve obstetric, perinatal and neonatal outcomes. 
Opioid substitution maintenance therapy also has an important 
role in attracting and retaining pregnant women in treatment and 
ensuring good contact with obstetric and community-based ser-
vices including primary care. Addressing childcare and family sup-
port issues for women continues to be a major gap in the delivery 
of services for women in most countries.
27
59 Compared to the general population, other psychiatric conditions 
are relatively more common amongst people with drug depen-
dence. The presence of comorbid psychiatric conditions increases 
the risk of treatment failure. Services need to be aware of these 
issues and should provide additional services as needed to manage 
psychiatric conditions present in addition to opioid dependence.
60 People with opioid dependence and IDUs frequently use a range 
of psychoactive substances in addition to opioids, including alco-
hol. Research has shown that the use of cocaine in combination 
with opioids is, in particular, a factor that is associated with treat-
ment failure. In addition, where drugs such as cocaine are used 
by injection, the effectiveness of opioid substitution therapy in 
managing risk behaviours is reduced. At the same time, research 
evidence indicates that when individuals with opioid dependence 
are retained in treatment, levels of use of cocaine are reduced, 
along with levels of opioid use.
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Regulation of opioid substitution therapy 
and training
61 Substitution therapy for opioid dependence must be subject to 
principles of good medical practice. Evidence-based guidelines are 
in place in many countries, and need to be elaborated where they 
are not. Such guidelines should include criteria to define who are 
considered eligible for substitution therapy as well as contraindi-
cations, and should outline best practices in clinical management, 
as well as relevant government regulations. Efforts should be 
made to ensure that guidelines are widely disseminated and pro-
grammes for monitoring treatment quality and outcomes are put 
in place. 
62 Opioid substitution maintenance therapy should be restricted 
to people who meet the clinical criteria for opioid dependence. 
However, excessive restrictive regulations regarding criteria for 
placement in substitution maintenance therapy and its provision, 
that have no significant effect on quality of provided treatment, 
are counterproductive with regard to access to treatment and HIV/
AIDS prevention. Issues such as the maximum dose or maximum 
length of treatment should be left to the practitioner’s clinical jud-
gement, based on the assessment of the individual patient. 
63 The registration/accreditation of treatment providers and registra-
tion of those receiving treatment, are useful approaches to ensure 
the quality of service and to minimize the risk of prescribed medi-
cations being diverted into illicit channels.
29
64 The introduction and expansion of substitution maintenance treat-
ment programmes comes with the need to train practitioners. The 
target groups for substitution opioid pharmacotherapy training 
include: medical practitioners involved in prescribing and delive-
ring treatment to people with substance use disorders; pharmacists 
involved in dispensing medications; alcohol and drug counsellors 
working with clients of substitution maintenance treatment pro-
grammes; health practitioners associated with infectious disease 
programmes; and general health professionals who may come into 
contact with clients on these programmes (such as ambulance offi-
cers, accident and emergency staff, general practitioners).

Conclusions
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65 Opioid dependence is a complex condition that often requires 
long-term treatment and care. No single treatment modality is 
effective for all people with opioid dependence. Adequate access 
to a wide range of treatment options should be offered to respond 
to the varying needs of people with opioid dependence.
66 Substitution maintenance treatment is an effective, safe and cost-
effective modality for the management of opioid dependence. 
Repeated rigorous evaluation has demonstrated that such treat-
ment is a valuable and critical component of the effective manage-
ment of opioid dependence and the prevention of HIV among IDUs. 
67 There is mounting evidence that improved outcomes from opioid 
substitution maintenance therapy arise from timely entry into 
treatment, longer duration and continuity of treatment, and ade-
quate doses of medication. 
68 Individuals with opioid dependence benefit from substitution 
maintenance therapy through increased stability and improved 
well-being and social functioning. People receiving substitution 
therapy can make significant progress in their physical and emo-
tional life, as well as in their relationships with others and their 
ability to contribute meaningfully to their community and society 
at large. 
69 Society as a whole benefits from substitution maintenance the-
rapy through reductions in the incidence of criminal behaviour, 
reduced health and criminal justice system costs, reduced risks of 
transmission of HIV and other bloodborne viruses, and increased 
productivity. There is a strong case for investing in opioid substi-
tution maintenance therapy, as the savings resulting from treating 
an individual far exceed the costs. 
70 Provision of substitution maintenance therapy of opioid depen-
dence is an effective HIV/AIDS prevention strategy that should be 
considered for implementation – as soon as possible – for IDUs 
with opioid dependence in communities at risk of HIV/AIDS epi-
demics. Once HIV has been introduced into a local community of 
IDUs, there is the possibility of extremely rapid spread. Provision of 
substitution maintenance therapy should be integrated with other 
HIV preventive interventions and services, as well as with those for 
treatment and care of people living with HIV/AIDS. 
71 The practice of substitution maintenance therapy must be guided 
by research evidence and supported by adequate training and 
evaluation. Possible adverse consequences need to be minimized 
by adhering to best clinical practices, monitoring treatment qua-
lity and outcomes, and instituting adequate control measures and 
regulations to avoid diversion of the medicines into illicit channels.
The World Health Organization (WHO), the United Nations Office 
on Drugs and Crime (UNODC) and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), have developed a joint posi-
tion on substitution maintenance therapy for opioid dependen-
ce. Based on a review of scientific evidence and oriented towards 
policymakers, the WHO/UNODC/UNAIDS position paper covers a 
wide range of issues, from the rationale for this treatment moda-
lity, to the specific considerations regarding its provision for 
people with HIV/AIDS.
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